SRPTSarepta Therapeutics, Inc.
What is the market doing?
The market is leaning against it: in a downtrend (−7% vs 200-day) and a crowded short (+21% of shares).
In a downtrend, below its 50- and 200-day averages. Price is −7% vs its 200-day average.
A crowded short, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How SRPT is trading
Sarepta Therapeutics, Inc. is +2.4% over the past year while the S&P 500 is +18%: 16 points behind the market.
1-year return · S&P 500 +18%
- vs 200-day average
- −7.3%
vs 200-day average · below trend, but not far
- RSI (14)
- 32
RSI (14) · neutral
- Below its 52-week high
- 27%
Below its 52-week high
Details›
- Last close2026-10-09
- $17.85
- 1 monthS&P 500 +2.7%
- −13%
- 1 yearS&P 500 +18%
- +2.4%
- 5 yearsS&P 500 +88%
- −78%
- vs 50-day average$18.96
- −5.8%
- 52-week high
- $24.45
- 52-week low
- $15.00
- Annualised volatility
- 88%
| Year | Return |
|---|---|
| 2026 (year to date) | −17% |
| 2025 | −82% |
| 2024 | +26% |
| 2023 | −26% |
| 2022 | +44% |
| 2021 | −47% |
| 2020 | +32% |
| 2019 | +18% |
| 2018 | +96% |
| 2017 | +103% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 10 | 4 of 10 | −1.1% |
| Feb | 10 | 4 of 10 | −1.6% |
| Mar | 10 | 5 of 10 | −2.7% |
| Apr | 10 | 3 of 10 | +1.2% |
| May | 10 | 6 of 10 | −1.2% |
| Jun | 10 | 7 of 10 | +4.8% |
| Jul | 11 | 3 of 11 | +1.5% |
| Aug | 11 | 8 of 11 | +6.3% |
| Sep | 11 | 7 of 11 | +14% |
| Oct | 11 | 5 of 11 | −6.3% |
| Nov | 10 | 7 of 10 | +6.1% |
| Dec | 10 | 6 of 10 | +2.8% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.